<DOC>
	<DOCNO>NCT02466386</DOCNO>
	<brief_summary>To evaluate long-term safety SPD489 administer daily morning dose ( 5 , 10 , 15 , 20 , 30 mg/day ) preschool child diagnose Attention-deficit/Hyperactivity Disorder ( ADHD ) . Subjects enrol study antecedent study SPD489-211 ( NCT02402166 ) SPD489-347 .</brief_summary>
	<brief_title>Safety Tolerability Study SPD489 Preschool Children Aged 4-5 Years , Diagnosed With Attention-deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Subject male female age 45 year inclusive time consent antecedent SPD489 trial preschool ADHD population . 2 . For `` A '' Subjects : Subject know dose SPD489 complete final visit treatment phase unblinded antecedent study without experience clinically significant AEs would preclude exposure SPD489 directly enter study without gap antecedent study study ( define â‰¤3 day since last dose prior study ) , OR For `` B '' Subjects : Subject require dose titration complete least dose optimization follow blind antecedent study without experience clinically significant AEs would preclude exposure SPD489 , OR For `` B '' Subjects : Subject complete final visit treatment phase unblended antecedent study without experience clinically significant AEs would preclude exposure SPD489 , enroll study within 3 day ( i.e. , &gt; 3 day since last dose prior study ) . 3 . Subject 's parent LAR must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction accordance ICH GCP Guideline E6 ( 1996 ) applicable regulation , complete studyrelated procedure . 4 . Subject parent/LAR willing able comply test requirement define protocol , include oversight morning dosing . Specifically , parent/LAR available dispense dose investigational product study duration . 5 . For `` A '' Subjects : Subject satisfactory medical assessment clinically significant relevant abnormality determine physical examination finding vital sign result would preclude treatment SPD489 . For `` B '' Subjects : Subject satisfactory medical assessment clinically significant relevant abnormality determine physical examination finding clinical laboratory test result , ECG result , vital sign result would preclude treatment SPD489 . 6 . Subject live parent guardian &gt; 6 month . 1 . Subject terminate antecedent SPD489 trial noncompliance and/or experience SAE AE result termination previous SPD489 trial . 2 . Subject experience clinically significant AEs previous SPD489 trial , opinion investigator , would preclude exposure SPD489 . 3 . Subject require anticipates need take medication central nervous system effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . 4 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment conduct study might increase risk subject . Similarly , subject exclude additional condition ( ) , investigator 's opinion , would prohibit subject completing study would best interest subject . The additional condition ( ) would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . 5 . Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . 6 . Subject know family history sudden cardiac death ventricular arrhythmia . 7 . Subject blood pressure measurement &gt; 95th percentile age , sex , height Visit 0 . 8 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem place increased vulnerability sympathomimetic effect stimulant drug . 9 . Subject current diagnosis adjustment disorder , autism , psychosis , bipolar disorder . 10 . Subject currently consider risk suicide opinion investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment investigator . 11 . Subject history seizure ( infantile febrile seizure ) current diagnosis Tourette 's Disorder . 12 . Subject chronic current tic disorder judge investigator exclusionary 13 . Subject take medication exclude per protocol . 14 . For `` B '' Subjects : Subject clinically significant ECG clinical laboratory abnormality Screening Visit ( Visit 1 ) . 15 . For `` B '' Subjects : Subject current abnormal thyroid function , define abnormal TSH T4 Screening Visit ( Visit 1 ) Visit 0 . Treatment stable dose thyroid medication least 3 month permit</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>